首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1744760

全球介入性腫瘤消融市場

Interventional Oncology Ablation

出版日期: 2025年06月06日 | 出版商:

Global Industry Analysts, Inc. | 英文 373 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球介入性腫瘤消融市場規模將達 8.84 億美元

全球介入性腫瘤消融市場規模預計在2024年為5.632億美元，到2030年將達到8.84億美元，在2024-2030年的分析期間內，複合年成長率為7.8%。射頻消融術是本報告分析的細分市場之一，預計其複合年成長率為9.1%，到分析期結束時規模將達到4.695億美元。微波消融細分市場在分析期間內的複合年成長率估計為5.4%。

美國市場規模估計為 1.534 億美元，中國市場預計複合年成長率為 12.4%

美國介入性腫瘤消融市場規模預計在2024年達到1.534億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到1.908億美元，在2024-2030年的分析期間內，複合年成長率為12.4%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.8%和7.6%。在歐洲，預計德國市場的複合年成長率為5.2%。

全球介入性腫瘤消融市場－主要趨勢與促進因素摘要

介入性腫瘤學為什麼消融術成為癌症治療的重要方式？

介入性腫瘤消融已成為固態腫瘤微創治療中重要的局部、影像引導治療方法，為傳統手術切除和全身性治療提供了一種替代方案。該技術使用基於能量的設備，例如射頻 (RF)、微波、冷凍消融和不可逆電穿孔，無需開放性手術即可破壞癌化組織。它最常用於肝、肺、腎、骨和軟組織腫瘤患者，尤其是在因腫瘤位置、大小或患者併發症而無法進行手術的情況下。

介入性腫瘤消融術利用超音波、CT和MRI等技術，精準度高，在標靶治療的同時保護周邊健康組織。它擴大與化療和免疫療法等全身療法聯合使用，或作為移植或手術的過渡治療。由於對創傷更小、門診治療、恢復更快、併發症更少、費用更低的癌症治療的需求，腫瘤切除術已成為早期或寡轉移性疾病治療的首選方案。

哪些技術正在提升介入性腫瘤學中的腫瘤消融能力？

介入性腫瘤消融：該領域正在經歷重大技術進步，尤其是在消融設備設計、影像導引系統和熱控制演算法方面。微波消融系統以其比射頻消融更高的溫度和更快的消融時間而聞名，在治療大型深層腫瘤方面越來越受到青睞。冷凍消融系統可以提高治療過程中的可視性，並且常用於精確切緣至關重要的治療，例如腎臟腫瘤和前列腺腫瘤。

先進的影像導引技術，包括即時3D導航、造影超音波和磁振造影測溫，正在提高消融的精確度和手術安全性。機器人技術和人工智慧驅動的軟體平台的創新也使治療結果更加可預測，並擴大了可經皮治療的腫瘤的複雜性。此外，電極設計、冷卻機制和多探頭同步技術的進步，正在提高腫瘤覆蓋率、降低復發率，並提高同時治療多個病灶的能力。

非熱消融技術，例如不可逆電穿孔 (IRE)，也正在被探索。 IRE 利用電脈衝使細胞膜通透並誘導細胞凋亡，且無需顯著加熱。 IRE 適用於治療靠近膽管和血管等關鍵結構的腫瘤。這些不斷擴展的治療選擇正在擴大介入腫瘤治療的範圍和安全性。

哪些患者群體和臨床環境推動了消融療法的採用？

患有無法切除或醫學上無法手術的腫瘤的患者是介入性腫瘤消融術的首選。該療法常用於治療肝細胞癌 (HCC) 和結直腸癌肝轉移，對早期患者俱有治癒潛力，對晚期患者俱有姑息治療作用。肺癌和腎癌也常採用經皮消融術治療，尤其是在併發症導致無法手術的患者。

腫瘤中心、三級醫院和門診介入放射診所是消融治療的主要場所。介入性腫瘤學日益融入多學科癌症護理團隊，以消融術補充外科手術、全身性治療和放射線治療，正在推動消融術的更廣泛應用。在許多醫療保健系統中，診斷影像、微創基礎設施和專科培訓的普及正在推動消融術的普及。此外，患者對個人化、低創傷治療方案的需求，也促使他們更偏好消融術，而非更具侵入性的介入措施。

介入性腫瘤消融市場的成長受到多種因素的推動…

介入性腫瘤消融市場的成長受到多種因素的推動，包括全球癌症發生率的上升、對微創治療的需求不斷成長，以及影像引導介入技術的創新。隨著癌症治療向個人化、標靶化和低損傷性治療模式發展，消融為不適合傳統手術且希望避免全身毒性的患者提供了極具吸引力的解決方案。熱消融和非熱消融技術的進步正在擴大可治療腫瘤的範圍，並改善治癒性和安寧療護的療效。

醫療保健系統越來越認知到消融治療的成本效益，住院率的降低和康復速度的加速轉化為顯著的經濟節省，尤其是在門診和日托機構。報銷制度的改善、新設備的監管核准以及將消融治療納入主要治療指南，進一步加速了市場應用。此外，將消融聯合治療使用，正在為癌症治療開闢新的領域。隨著介入性腫瘤學逐漸融入主流腫瘤治療途徑，未來幾年腫瘤切除術預計將在全球強勁擴張。

部分

技術（射頻消融、微波消融、冷凍消融、不可逆電穿孔消融）；適應症（肝癌、腎癌、肺癌、其他適應症）；最終用戶（醫院和診所、門診手術中心、其他最終用戶）

受訪企業範例（共34家）

Abbott Laboratories
AngioDynamics
Boston Scientific Corporation
CASCINATION AG
Cook Medical
DFINE, Inc.
EDAP TMS SA
GE HealthCare
HealthTronics
Intuitive Surgical
Medtronic plc
Merit Medical Systems, Inc.
Profound Medical
STARmed Co., Ltd.
Stryker Corporation
Teleflex Incorporated
Terumo Corporation
Varian Medical Systems（now part of Siemens Healthineers）
Visionect doo
ZAP Surgical Systems, Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

The global market for Interventional Oncology Ablation estimated at US$563.2 Million in the year 2024, is expected to reach US$884.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$469.5 Million by the end of the analysis period. Growth in the Microwave Ablation segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$153.4 Million While China is Forecast to Grow at 12.4% CAGR

The Interventional Oncology Ablation market in the U.S. is estimated at US$153.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$190.8 Million by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Interventional Oncology Ablation Market - Key Trends & Drivers Summarized

Why Is Interventional Oncology Ablation Emerging as a Critical Modality in Cancer Treatment?

Interventional oncology ablation has become an essential therapeutic approach in the minimally invasive treatment of solid tumors, offering a localized, image-guided alternative to traditional surgical resection and systemic therapies. This technique involves the use of energy-based devices-such as radiofrequency (RF), microwave, cryoablation, and irreversible electroporation-to destroy cancerous tissues without the need for open surgery. It is most frequently used for patients with liver, lung, kidney, bone, and soft tissue tumors, particularly when surgery is not feasible due to tumor location, size, or patient comorbidities.

The precision of interventional oncology ablation, guided by modalities such as ultrasound, CT, or MRI, enables targeted treatment while sparing healthy surrounding tissue. It is increasingly used in combination with systemic therapies like chemotherapy and immunotherapy, or as a bridge to transplantation or surgery. The demand for less invasive, outpatient-based cancer treatments with faster recovery, fewer complications, and cost savings is making tumor ablation a preferred option in early-stage or oligometastatic disease management.

What Technologies Are Advancing the Capabilities of Tumor Ablation in Interventional Oncology?

The interventional oncology ablation field is undergoing significant technological advancement, particularly in ablation device design, image-guidance systems, and thermal control algorithms. Microwave ablation systems, known for their ability to achieve higher temperatures and faster ablation times than RF ablation, are increasingly favored in treating large and deep-seated tumors. Cryoablation systems provide enhanced visualization during treatment and are often used where precision margins are critical, such as in renal or prostate tumors.

Advanced image-guidance technologies-including real-time 3D navigation, contrast-enhanced ultrasound, and MR thermometry-are improving ablation accuracy and procedural safety. Innovations in robotics and AI-driven software platforms are also enabling more predictable outcomes and expanding the complexity of tumors that can be treated percutaneously. Furthermore, developments in electrode design, cooling mechanisms, and multiprobe synchronization are supporting better tumor coverage, reduced recurrence rates, and the ability to treat multiple lesions simultaneously.

Research is also progressing in non-thermal ablation modalities, such as irreversible electroporation (IRE), which uses electrical pulses to permeabilize cell membranes and induce apoptosis without significant heating-making it suitable for tumors near critical structures like bile ducts and blood vessels. These expanding options are broadening the scope and safety of interventional oncology treatments.

Which Patient Populations and Clinical Settings Are Driving Adoption of Ablative Therapies?

Patients with unresectable or medically inoperable tumors are the primary candidates for interventional oncology ablation. The approach is commonly adopted in hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer, where it offers curative potential in early-stage disease and palliative benefits in advanced cases. Lung and kidney tumors are also frequently managed using percutaneous ablation, especially in patients with comorbidities that preclude surgery.

Oncology centers, tertiary hospitals, and outpatient interventional radiology clinics are major settings for ablation procedures. Growing integration of interventional oncology into multidisciplinary cancer care teams is facilitating broader adoption, where ablation complements surgery, systemic therapy, and radiotherapy. In many healthcare systems, increasing access to diagnostic imaging, minimally invasive infrastructure, and specialist training is enhancing procedural uptake. Moreover, patient demand for personalized, low-trauma treatment options is shifting preferences toward ablation over more invasive interventions.

The Growth in the Interventional Oncology Ablation Market Is Driven by Several Factors…

The growth in the interventional oncology ablation market is driven by several factors including rising global cancer incidence, increasing demand for minimally invasive therapies, and technological innovation in image-guided intervention. As oncology care evolves toward personalized, targeted, and less disruptive treatment paradigms, ablation offers a compelling solution for patients who are not candidates for traditional surgery or wish to avoid systemic toxicity. Advances in thermal and non-thermal ablation technologies are expanding the range of treatable tumors and improving outcomes in both curative and palliative settings.

Healthcare systems are increasingly recognizing the cost-effectiveness of ablation, particularly in outpatient and day-care settings, where reduced hospitalization and faster recovery translate into significant economic savings. Reimbursement improvements, regulatory approvals of new devices, and the inclusion of ablation in major treatment guidelines are further accelerating market adoption. Additionally, the increasing use of ablation as part of combination therapy with immuno-oncology agents is opening new frontiers in cancer treatment. As interventional oncology becomes more integrated into mainstream oncology pathways, tumor ablation is poised for robust global expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Interventional Oncology Ablation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation); Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Other Indications); End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

Abbott Laboratories
AngioDynamics
Boston Scientific Corporation
CASCINATION AG
Cook Medical
DFINE, Inc.
EDAP TMS S.A.
GE HealthCare
HealthTronics
Intuitive Surgical
Medtronic plc
Merit Medical Systems, Inc.
Profound Medical
STARmed Co., Ltd.
Stryker Corporation
Teleflex Incorporated
Terumo Corporation
Varian Medical Systems (now part of Siemens Healthineers)
Visionect d.o.o.
ZAP Surgical Systems, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Interventional Oncology Ablation - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Global Cancer Incidence Propels Demand for Minimally Invasive and Targeted Tumor Ablation Techniques
- Increasing Adoption of Image-Guided Interventional Oncology Supports Growth of Thermal and Non-Thermal Ablation Procedures
- Technological Advancements in Radiofrequency, Microwave, and Cryoablation Devices Enhance Precision and Treatment Outcomes
- Shift Toward Day-Care and Outpatient Oncology Models Strengthens the Business Case for Non-Surgical Tumor Ablation
- Growing Clinical Preference for Organ-Preserving Therapies Fuels Use of Ablation in Early-Stage and Non-Resectable Tumors
- Improved Access to Advanced Imaging Modalities Drives Wider Use of Image-Guided Tumor Localization in Ablation Procedures
- Integration of Interventional Oncology Into Multidisciplinary Cancer Care Expands Application Scope in Liver, Kidney, Lung, and Bone Tumors
- Rising Demand for Repeatable and Low-Morbidity Therapies Encourages Adoption of Ablation Over Radiation or Systemic Therapies
- FDA Approvals and Expanding Clinical Guidelines Boost Market Confidence in Interventional Ablation as a Standard of Care
- Advancements in Ablation Applicators and Energy Delivery Systems Enhance Control, Accuracy, and Real-Time Feedback
- Rise of Robotic and AI-Enhanced Image Navigation Systems Improves Targeting Accuracy and Minimizes Complications in Ablation
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Interventional Oncology Ablation Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Interventional Oncology Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Radiofrequency Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Microwave Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Cryoablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Irreversible Electroporation Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Kidney Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 38: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: USA Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 40: USA 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 41: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
CANADA
- TABLE 47: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: Canada Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: Canada 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 50: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 53: Canada Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
JAPAN
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 56: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: Japan Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: Japan 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 59: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 62: Japan Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
CHINA
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 65: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: China Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: China 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 68: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 71: China Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
EUROPE
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 74: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 75: Europe Historic Review for Interventional Oncology Ablation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: Europe 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 77: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
FRANCE
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 86: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: France Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: France 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 89: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 92: France Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
GERMANY
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 95: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 96: Germany Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 97: Germany 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 98: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 101: Germany Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
ITALY
- TABLE 104: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 105: Italy Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 106: Italy 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 107: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 110: Italy Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 113: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 114: UK Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 115: UK 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 116: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 119: UK Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
SPAIN
- TABLE 122: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 123: Spain Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 124: Spain 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 125: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 126: Spain Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 127: Spain 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 128: Spain Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 131: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 132: Russia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 133: Russia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 134: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 135: Russia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 136: Russia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 137: Russia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 141: Rest of Europe Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 142: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 150: Asia-Pacific Historic Review for Interventional Oncology Ablation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 151: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 153: Asia-Pacific Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 154: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
AUSTRALIA
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 161: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 162: Australia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 163: Australia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 164: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 165: Australia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 166: Australia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 167: Australia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
INDIA
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 170: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 171: India Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 172: India 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 173: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 174: India Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 175: India 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 176: India Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 179: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 180: South Korea Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 181: South Korea 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 182: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 183: South Korea Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 184: South Korea 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 189: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
LATIN AMERICA
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 197: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 198: Latin America Historic Review for Interventional Oncology Ablation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 199: Latin America 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 200: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 201: Latin America Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 202: Latin America 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 209: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 210: Argentina Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 211: Argentina 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 212: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 213: Argentina Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 214: Argentina 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 218: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 219: Brazil Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 220: Brazil 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 221: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 222: Brazil Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 223: Brazil 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
MEXICO
- TABLE 227: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 228: Mexico Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 229: Mexico 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 230: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 231: Mexico Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 232: Mexico 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 237: Rest of Latin America Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 238: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Latin America Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
MIDDLE EAST
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 245: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 246: Middle East Historic Review for Interventional Oncology Ablation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 247: Middle East 15-Year Perspective for Interventional Oncology Ablation by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 248: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 249: Middle East Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 250: Middle East 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
IRAN
- TABLE 257: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 258: Iran Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 259: Iran 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 260: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 261: Iran Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 262: Iran 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 263: Iran Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 266: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 267: Israel Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 268: Israel 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 269: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 270: Israel Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 271: Israel 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 272: Israel Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 276: Saudi Arabia Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 277: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 279: Saudi Arabia Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 280: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 284: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 285: UAE Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 286: UAE 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 287: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 288: UAE Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 289: UAE 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 290: UAE Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 294: Rest of Middle East Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 295: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Middle East Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030
AFRICA
- Interventional Oncology Ablation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 302: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 303: Africa Historic Review for Interventional Oncology Ablation by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 304: Africa 15-Year Perspective for Interventional Oncology Ablation by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation and Irreversible Electroporation Ablation for the Years 2015, 2025 & 2030
- TABLE 305: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 306: Africa Historic Review for Interventional Oncology Ablation by End-user - Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 307: Africa 15-Year Perspective for Interventional Oncology Ablation by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
- TABLE 308: Africa Recent Past, Current & Future Analysis for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Interventional Oncology Ablation by Indication - Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Interventional Oncology Ablation by Indication - Percentage Breakdown of Value Sales for Liver Cancer, Kidney Cancer, Lung Cancer and Other Indications for the Years 2015, 2025 & 2030